A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
|2||Active, not recruiting||
A Phase 2, Multicenter, Randomized Study of AP26113
ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients
|4||Not yet recruiting||
Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors
An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer
† Study has passed its completion date and status has not been verified in more than two years.